


SUPERSTOCK Investor



This tiny R&D company can make you healthy *and...* **MAKE YOU RICH!**

When the FDA approves their cancer vaccine, the stock could go from \$1 to \$100 a share...as crazy as that sounds.

But even if that doesn't happen, early investors could see a 900% return when the technology is applied successfully in an entirely different field – veterinary medicine!

By Jay London, *SuperStock Investor*

In a well-equipped laboratory at a major university, a small group of scientists recently made an amazing discovery.

They found that, almost universally, all cancer patients have an elevated level of a substance in the body known as "P65."

P65 is a special type of protein molecule, made in the body in significant quantities only when cancer is present.

Its production is controlled by a specific gene, which the research team has identified; let's call it the

(continues on page 3...)

Imagine getting vaccinated against cancer like you do for small pox!

ALL CONTENT AND STATEMENTS CONTAINED HEREIN REGARDING XPENTION GENETICS INC. HAVE BEEN APPROVED BY MANAGEMENT OF XPENTION GENETICS INC. , AND ARE APPROVED FOR PUBLIC DISSEMINATION. THIS APPROVAL IS SUBJECT TO THE 1933 FOWARD LOOKING STATEMENT ACT AND THE DISCLAIMER ATTACHED BY:

NAME

TITLE

DATE

Imagine turning \$10,000 into \$20,000 in just one day ... over and over again ... every time an overpaid Wall Street investment banker closes another corporate takeover deal!

Dear Investor:

Hello. My name is Jay London. I'm the executive publisher of *Superstock Investor*, a monthly newsletter that specializes in uncovering stocks ripe for a takeover, or poised to appreciate due to a special situation.

For more than 27 years *Superstock Investor* has earned a reputation for being the prime resource for spotting stocks ripe for takeover.

Why look for companies that are takeover targets? Because mergers can drive stock prices higher — 20%, 40%, 50%, or more, sometimes in a single day — when the offers roll in.

When companies in virtually any industry – whether it's utilities, software, telecom, or transportation — are acquired ...

... their shareholders make big piles of money fast.

There's no better position to be in than owning shares of a company that's being targeted for take-over.

Historically, whenever an acquisition takes place, the stock of the company being bought goes up. Often by a lot — and often very fast.

Even the mere *hint* of a corporate take-over rumor can drive shares rapidly through the roof.

For instance, when Sun Gard Data Systems moved to buy out Caminus in December of 2002, Caminus was selling for \$2.34 a share.

After completion of the acquisition in January 2003, Caminus almost *quadrupled*: the stock shot up to \$8.75, giving shareholders a 273.93% gain in less than 4 weeks.

And when Computer Associates set its sights on Platinum Technology, the stock was at \$10.

Shortly after the buy-out, Platinum shares were selling for \$29.25. The stock had *tripled*! If you had bought 1,000 shares of Platinum, your original investment of \$10,000 would have grown to \$29,250.

Then there's the buyout of Lilly Indu by Valspar for \$12 a share.

On the strength of the deal, the market rewarded Lilly Indu shareholders by driving the stock price up to \$31.75. Within a few weeks, they *tripled their money!*

Want more evidence that a take-over can send share prices through the roof?

- Avnet bought Marshall Indus at \$19. Post-acquisition, Marshall shares went to \$39, a 105% gain. You would have doubled your money on the stock!
- Based on an announcement that they were courting an acquisition offer from an unnamed buyer, Merant stock rose 30% in a single week – despite the negative news that they had posted a loss of \$16.8 million in their most recent quarter and downsized 750 of their 2,200 employees.
- In December 1999, retailer CompUSA was selling for \$6.25 a share. But after corporate raider Grupo Sanborns made a tender offer to buy CompUSA for \$800

(continues on page 13...)

2 ADVERTISEMENT – Please see important disclosure on page 12. Always perform your own due diligence.

ALL CONTENT AND STATEMENTS CONTAINED HEREIN REGARDING XPENTION GENETICS INC. HAVE BEEN APPROVED BY MANAGEMENT OF XPENTION GENETICS INC. , AND ARE APPROVED FOR PUBLIC DISSEMINATION. THIS APPROVAL IS SUBJECT TO THE 1933 FOWARD LOOKING STATEMENT ACT AND THE DISCLAIMER ATTACHED BY:

NAME

TITLE

DATE

(continued from cover...)

“P65 gene.”

Here's what the scientists found...

Even in the earliest stages of cancer – before the cancer can be detected by any other method or test — a simple test shows an increase in the level of P65 present in the patient's bloodstream.

In fact, elevated P65 levels are a precursor of cancer. *The P65 level rises even in those patients who are about to develop cancer.*

Once the cancer is more advanced and a visible tumor has actually formed, P65 levels are even higher.

The ease by which P65 can be measured ... and the fact that it is the first indicator of cancer activity in the body to show up in a test of any sort ...

... means the scientists have stumbled onto an incredible biotechnology breakthrough: *the world's most effective medical test for early detection of cancer.*

Unlike other proteins, which are specific to different types of cancer (alpha-fetoprotein, for instance, is used to detect liver cancer), P65 appears to be a “universal molecular marker” ... with elevated P65 levels occurring in virtually every type of cancer.



Early detection of cancer can save your life – and the lives of those you love – as well as the lives of millions of other people (see article on page 4).

But that's not all...

The scientists wanted to see whether, by controlling a patient's P65 level, they could actually stop – even reverse – the cancer.

They discovered a chemical agent that could effectively block the production of P65 in the body.

And by stopping the body from making P65, they were actually able to slow – even halt – further growth of the cancer cells!

They also experimented with a gene therapy designed to control the gene that regulates

P65 production directly.

There too, by stopping more P65 from being produced in the body, they could prevent the cancer from growing further.

This means that P65 can do more than just detect cancer early, in time for life-saving treatment.

The combination of chemical and gene therapies now being developed by the researchers to lower P65 levels will, within a few years, be sold as the world's first effective cancer treatment and vaccine.

“The idea of a therapeutic cancer vaccine isn't just a dream; it's finally something that is potentially within our grasp.”

— J. Mark Lievonon,
President, Aventis
Pasteur Limited

Xpention Genetics, Inc.
(symbol: **XPNG**) – a biotechnology start-up was recently
(continues...)

Company Xpention
Stock symbol XPNG
Current share price . . . \$1.09
For a FREE Investor's Kit call:
1-888-XXX-XXX

Early cancer detection with Xpention's P65 breakthrough technology.

Double your lifespan – and your money!

Although Xpention's P65 breakthrough is the most promising cancer vaccine technology of the 21st century, the first application of P65 will be in tests for early detection of cancer.

This alone has the potential to literally save millions of lives. Here's why....

Cancer is the #2 killer in America, after heart disease. More than one out of three Americans will get cancer in his or her lifetime.

But for most forms of cancer, early detection translates directly into a longer lifespan for the patient.

Prostate cancer, for instance, is the second-most deadly cancer among American men, just behind lung cancer.

About 40,000 men die each year after cancer in their prostates metastasizes to their bones, lungs, and other organs.

But with early detection and diagnosis, 90% of prostate cancer patients live at least 5 years

beyond their diagnosis ... and two-thirds live 10 years or more.

Another example: colon cancer. More than 90% of people diagnosed with colon cancer are 50 or over. And nearly 60,000 Americans die each year from colon cancer.

But experts say that number could be cut in half if everyone over age 50 got tested for the disease.

The bottom line:

Investing in Xpention helps fund their R&D program to bring early detection tests for many different kinds of cancer to market sooner – potentially saving your life or the life of someone you love.

Investors can own Xpention today for around \$1 a share – and the target price for the stock once the first early detection cancer tests are marketed in 2007 is \$10 a share. Your profit: 900%.

For a FREE Investor's Kit on Xpention – including the facts on early cancer detection – call toll-free 1-888-XXX-XXX.



formed to commercialize the P65 technology ... and bring it to the health care marketplace.

And with one out of three Americans getting cancer, the market for P65 early detection tests and cancer vaccines is enormous – big enough to earn huge gains for alert early-stage investors who get in.

Up to 99.99% accurate in early detection of cancer

Almost half the men in America ... and a third of American women ... will get cancer during their life time.

Cancer is the second leading cause of death in the U.S. behind heart disease, causing one out of every four deaths.

“Investors can own Xpention today for around \$1 a share – and the target price for the stock once the first early detection cancer tests are marketed in 2007 is \$10 a share. Your profit: 900%.”

This year, about 570,280 Americans are expected to die of cancer – more than 1,500 people every day.

In the short-term, the key to avoiding cancer ... and living

4 ADVERTISEMENT – Please see important disclosure on page I2. Always perform your own due diligence.

ALL CONTENT AND STATEMENTS CONTAINED HEREIN REGARDING XPENTION GENETICS INC. HAVE BEEN APPROVED BY MANAGEMENT OF XPENTION GENETICS INC. , AND ARE APPROVED FOR PUBLIC DISSEMINATION. THIS APPROVAL IS SUBJECT TO THE 1933 FOWARD LOOKING STATEMENT ACT AND THE DISCLAIMER ATTACHED BY:

NAME

TITLE

DATE

longer ... is early detection. The kind of early detection a P65 test can provide better than any other technology.

In a series of highly controlled experiments on laboratory animals, an elevated P65 level was found to be nearly 100% predictive of cancer: every animal with cancer had high P65 levels in their bloodstreams. No exceptions.

But how accurate is the P65 cancer test in humans? Very, as it turns out.



With a molecular weight of 65,000 (hydrogen has a molecular weight of one, by comparison), P65 is a relatively large molecule.

So it's easy to measure the quantity of P65 in plasma, blood serum, or tissue with monoclonal antibody technology.

The scientists took hundreds of blood samples from women with breast cancer ... and found elevated P65 levels in 88% of the female cancer patients.

The results were similar in blood samples taken from men with prostate cancer – approximately 85% to 90% of male cancer patients had the elevated levels of P65 in their bloodstream.

The obvious application of the P65 technology is in a commercially available, FDA-



approved blood test.

You'd go to the doctor, he'd draw a vial of blood and send it to the lab. If your P65 level is normal, you get a clean bill of health.

But if it looks even slightly elevated, you may have just saved your life through early detection of cancer that, if found later on, could have

(continues...)

It's raining cats, dogs, and *dollars* for Xpention shareholders!



Americans are pet-crazy. We love our loyal cats and dogs, our cuddly puppies and kittens. And we will do anything ... and spend almost any amount of money ... to keep them happy and healthy.

Americans have more than 60 million pet dogs. And, we spend over \$12 billion a year on veterinary care.

So, how much potential profit does this represent for

Xpention's cancer detection test for canines?

The veterinarian will perform Xpention's P65 test at a fee of only \$25 to the patient.

Once the dog's blood is drawn, the test kit is sent to Xpention for analysis.

It costs Xpention \$3 to perform the test – and of the \$25 retail fee, the vet keeps \$13 as his profit. That means the net profit per test to Xpention is \$9 per test.

Assuming only 10% of pets in the U.S. are given the test annually, we multiply the \$9 per test profit by 6 million dogs ... and Xpention has an immediate annual revenue stream (remember, the test must be done every year) of \$54 million in net profit!

And remember, the same test for early detection of cancer in canines will be adapted for felines ... and Americans have nearly 70 million pet cats.

That will more than double the net profits from Xpention's veterinary cancer detection test to over \$100 million a year.

And this is before Xpention's first early cancer detection test for humans ... or the cancer vaccine based on P65 ... is ever shipped out the door!

For a FREE Investor's Kit on Xpention – including the facts on the canine and feline cancer tests – call toll-free 1-888-XXX-XXX

meant a debilitating – even life-threatening – illness for you.

However, FDA approval and commercialization of the P65 cancer early detection test is still a few years away – probably around 2009.

But Xpention shareholders don't have to wait that long to see a handsome profit on their investment.

“More than 60 million Americans have a dog or cat, and if you are one of them, you know how much you love your pet. Almost two-thirds of American households include at least one dog.”

That's because another P65 product is literally months away from being introduced to the marketplace – and it doesn't have to pass an FDA trial of any kind!

Grab your share of the \$12 billion veterinary medicine market

Since the initial P65 experiments were performed on small animals – then dogs, the development of P65 technology for canine applications is farther along than any other application.

And dog health care is the first commercial market Xpention is

6 ADVERTISEMENT – Please see important disclosure on page I2. Always perform your own due diligence.

ALL CONTENT AND STATEMENTS CONTAINED HEREIN REGARDING XPENTION GENETICS INC. HAVE BEEN APPROVED BY MANAGEMENT OF XPENTION GENETICS INC. , AND ARE APPROVED FOR PUBLIC DISSEMINATION. THIS APPROVAL IS SUBJECT TO THE 1933 FOWARD LOOKING STATEMENT ACT AND THE DISCLAIMER ATTACHED BY:

NAME

TITLE

DATE

targeting, with cat health care right on its tail (forgive the pun).

More than 60 million Americans have a dog or cat, and if you are one of them, you know how much you love your pet. Almost two-thirds of American households include at least one dog.

Dogs get cancer at roughly the same rate as humans ... and cancer accounts for almost half of the deaths of pets over 10 years of age.

So next year or so, when you bring your pet into the vet for a check-up, don't be surprised if the doctor recommends an inexpensive test for canine or feline cancer....

Which he'll perform by extracting a small sample of your pet's blood — and sending it to Xpention for P65 analysis.

I'm sure you won't balk at the cost, which is a very reasonable \$25.

That's a small price to pay to help poochie or kittie live a longer, disease-free life. Not to mention avoiding thousands of dollars in vet bills you'd pay

(continues...)

Company Xpention
Stock symbol XPNG
Current share price . . . \$1.09
For a FREE Investor's Kit call:
1-888-XXX-XXX



Cancer Vaccine Breakthrough from the Largest Cancer Center in the World.

One of the reasons I am so confident in Xpention's P65 cancer technology ... aside from the published research that proves it works – is the pedigree of the research team behind it.

The early animal studies in which elevated P65 levels in rats and mice were demonstrated to be accurate markers of early stage cancer were performed at The University of Texas M.D. Anderson Cancer Center – one of the largest cancer centers in the world.

Subsequent canine studies were performed at The University of Texas M.D. Anderson Cancer Center and recently in cooperation with Colorado State University, which has one of the largest animal cancer centers in the country.

By verifying the results of the initial lab rat and mice studies with extensive canine testing before going to human trials, the P65 team at The University of Texas M.D. Cancer Center – led by Dr. Thomas Slaga – was able to accelerate the pace of research.

Reason: the life span of a dog is 1/7th the life span of a human, so results based on mortality can be obtained faster than with human subjects.

Xpention Genetics, Inc. has been formed to commercialize the P65 technology – both for the testing of P65 levels for early stage detection of cancer, as well as for development of an effective cancer vaccine.

Xpention has partnered with Dr. Tony Milici, CEO of GeneThera Inc., for the development and commercialization of the cancer vaccine. One of GeneThera's specialties is the genomic sequencing analysis of genes, which will aid in developing the most effective vaccine for controlling the P65-producing gene.

ADVERTISEMENT

7

ALL CONTENT AND STATEMENTS CONTAINED HEREIN REGARDING XPENTION GENETICS INC. HAVE BEEN APPROVED BY MANAGEMENT OF XPENTION GENETICS INC. , AND ARE APPROVED FOR PUBLIC DISSEMINATION. THIS APPROVAL IS SUBJECT TO THE 1933 FOWARD LOOKING STATEMENT ACT AND THE DISCLAIMER ATTACHED BY:


NAME

TITLE

DATE

THE ANTI-CANCER “SUPERSTARS”

Zbigniew Walaszek, Ph.D.
Chief Scientific Officer



Dr. Walaszek received his Ph.D. in bio-organic chemistry at Silesia Technical University. Today his research focuses on the control of the carcinogenic process by chemopreventive agents including beta-glucuronidase inhibitors with an emphasis on D-glucaro-1, 4-lactone (GL) and its precursors.

The goal of this research is to determine the mechanism of GL-mediated control of disease and to demonstrate that cancer and possibly cardiovascular disease risk can be decreased by administering GL and its precursors such as D-glucarates or analogs, or by modifying metabolic pathways involved in its biosynthesis.

David Kittrell, President



Mr. Kittrell received his B.A. in Economics from Davidson College in North Carolina in 1974 and his Master of Arts in Economics from the University of Miami in 1978. Mr. Kittrell held various positions with SunTrust Bank

in Florida, including, Vice President, International Division; Vice President and Manager, Real Estate Administration Department; Vice President, Commercial Real Estate Finance Department; Senior Vice President, Special Assets Group; Senior Vice President and Manager, Real Estate Finance; and Executive Vice President and Chief Credit Officer, Credit Administration Division (1978-1997).

From 1999 to 2001, he was a Broker Associate with Coldwell Banker Residential Brokerage in Colorado. Since 2001, Mr. Kittrell has been a Managing Broker with Coldwell Banker Residential Brokerage in Colorado.

if your furry friend got cancer later on.

The veterinary medicine community is so excited about Xpention’s canine and feline P65 cancer tests, several of the biggest players in the industry are vying to become Xpention’s development and distribution partner for the test.

The signing of that agreement

alone could potentially double Xpention’s stock price ... before the first P65 test is ever sold. As for sales forecasts: if only 10% of America’s 60 million dogs are tested for P65 annually, that will produce an immediate gross revenue stream for Xpention of \$150 million a year ... about 3 times the company’s current market capitalization.

Here’s the best part: there’s no waiting for the lengthy government bureaucratic approval process to bring the Xpention animal cancer test to market.

Because unlike human drugs and medical equipment, animal tests require no FDA approval – or any other regulatory agency approval – of any kind!

8 ADVERTISEMENT – Please see important disclosure on page I2. Always perform your own due diligence.

ALL CONTENT AND STATEMENTS CONTAINED HEREIN REGARDING XPENTION GENETICS INC. HAVE BEEN APPROVED BY MANAGEMENT OF XPENTION GENETICS INC. , AND ARE APPROVED FOR PUBLIC DISSEMINATION. THIS APPROVAL IS SUBJECT TO THE 1933 FOWARD LOOKING STATEMENT ACT AND THE DISCLAIMER ATTACHED BY:

NAME

TITLE

DATE



Xpention has put development of the canine cancer test on a fast track – so look for the canine cancer test to start generating revenues late in 2006 or early in 2007.

Get vaccinated against cancer as you do for small pox

Thanks to vaccinations, you and I are protected from diseases ranging from the flu and small pox, to TB and mumps.

Xpention is convinced that, within a few years, you will be able to go to the doctor and get vaccinated against cancer in much the same way.

Its' research team is working on two approaches to the cancer treatment.

The first is a chemical approach ... in essence, a combination of drugs that reduce or shut off P65 production in the human body ... and by doing so prevents

cancer cells from growing.

In the second, a vaccine, a genetically modified virus is inserted into a cell. Once inside the cell, it turns off the gene responsible for P65 production.

To put the market for an cancer vaccine into perspective, there are approximately 6 billion people on the planet.

Virtually every one of them is afraid of getting cancer. And likely, a third of them – 2 billion people – will get cancer at some point.

You can see that the health benefits ... and the profit potential ... of Xpention's cancer vaccine, now under development and targeted for a 2009 release date, are nearly incalculable.

To put the revenue potential into perspective, I'm sure you've driven by McDonald's and seen the signs proclaiming "billions sold."

“We’ve all read the hype about companies promising a cure for cancer...but P65 technology is the real thing.

I'm betting that Xpention will, within a few years, be able to post a similar sign on its Web site.

Except it won't be one-dollar hamburgers they're talking about, but vaccines that help prevent cancer by keeping P65 levels in your blood stream low.

And they'll be selling, not for a dollar a vaccine, but for \$10 ... or \$20 ... or any other price the company asks, because most of us would pay any price to be assured of a cancer-free future for life.

Which is exactly what Xpention's P65 cancer vaccine will offer!

(continues...)

How to buy Xpention

- 1.** For more information on the stock, call the Xpention Investor Relations Department toll-free at **1-888-XXX-XXX** today.
- 2.** Call your broker – or log onto your online brokerage account now.
- 3.** Place an order for shares of Xpention – stock symbol XPNG – today, before new announcements send the stock price higher.
- 4.** You can track the stock in your monthly issues of *Superstock Investor*.
- 5.** Visit Xpention's Web site at www.xpention.com for the latest investor news and updates.

ADVERTISEMENT

9

ALL CONTENT AND STATEMENTS CONTAINED HEREIN REGARDING XPENTION GENETICS INC. HAVE BEEN APPROVED BY MANAGEMENT OF XPENTION GENETICS INC. , AND ARE APPROVED FOR PUBLIC DISSEMINATION. THIS APPROVAL IS SUBJECT TO THE 1933 FOWARD LOOKING STATEMENT ACT AND THE DISCLAIMER ATTACHED BY:

NAME

TITLE

DATE

Timeline: \$1 billion market for Xpention P65 cancer vaccine by 2009:

—1994 Drs. Margaret Hanausek, Zbigniew Walazek, and Thomas Slaga were issued the first patent for using the P65 protein in cancer diagnosis.

—1995 Received the P65 patent for use on canines.

—1998 Received the p65 patent for use on humans.

Get in on the ground floor of the next big thing in biotech

So, what's ahead for Xpention and its shareholders?

Early-stage investors who get in now – like you and me – can own the next big biotech success story today for about a dollar a share ... a small fraction of what the stock will be worth in just a few years from now.

We've all read the hype about companies promising a cure for cancer ... but P65 technology is the real thing.

It's backed by years of solid basic and clinical research at the University of Texas M.D. Anderson Cancer Center –

10 good reasons why you should own Xpention today...

1. Cancer treatment is a \$69 billion market – and Xpention's technology is the most promising new cancer vaccine of the decade.
2. The stock is selling for \$1 a share today. When Xpention's cancer vaccine wins FDA approval, the price could hit \$100 a share – or higher.
3. The P65 cancer marker can also be used for early detection of prostate, breast, and many other cancers ... again, a multi-billion-dollar market.
4. Until Xpention's P65 technology is approved for human use, it has a more immediate application in veterinary medicine – a \$12 billion market – as an early cancer detection test for dogs and cats.
5. Xpention's cancer research is supported by the AMC Cancer Center and the University of Texas Health Science Center at San Antonio – two highly respected cancer research institutes.
6. The \$5.5 million R&D cost to develop the current P65 cancer technology has already been absorbed by early stage private investors ... stock holders are not paying its cost.
7. One out of three Americans will get cancer during his or her lifetime. Globally, billions of patients are waiting for Xpention's P65 cancer treatment.
8. At the current stock price, you can control approximately 10,000 shares with only a \$10,000 position in the company. Even a \$1 move up in stock price will give you a 100% gain on your investment.
9. Company insiders own half the shares; they would not invest millions of dollars of their own money in Xpention unless they were fairly certain a big pay-off was assured.
10. The success of Xpention's P65 cancer technology will make it an attractive take-over target for one of the large pharmaceutical companies. Even a rumor about possible acquisition interest can boost the stock price 50% to 100% or more.

10 ADVERTISEMENT – Please see important disclosure on page 12. Always perform your own due diligence.

ALL CONTENT AND STATEMENTS CONTAINED HEREIN REGARDING XPENTION GENETICS INC. HAVE BEEN APPROVED BY MANAGEMENT OF XPENTION GENETICS INC. , AND ARE APPROVED FOR PUBLIC DISSEMINATION. THIS APPROVAL IS SUBJECT TO THE 1933 FOWARD LOOKING STATEMENT ACT AND THE DISCLAIMER ATTACHED BY:

NAME

TITLE

DATE

—2004 Xpention is incorporated to commercialize P65 technology for human treatment. Annual sales: \$0. Stock price: \$1.

—2007 Xpention to introduce canine and feline P65-based test for early detection of cancer into \$12 billion veterinary market. Annual sales: \$150 million. Stock price: \$10.

—2008 Xpention P65-based test for early cancer detection approved by FDA for human testing. Annual sales: \$500 million. Stock price: \$50.

—2009 First P65-based cancer vaccine available in U.S. and overseas. Annual sales: \$1 billion. Stock price: \$100.

the largest and most respected cancer research facility on the planet.

The pioneering research in P65 – performed at the Anderson Cancer Center – cost approximately \$5.5 million in labor and materials. But in a shrewd investment, Xpention has acquired all rights to the P65 technology – at a tiny fraction of that cost.

As the timeline shows (see chart), the company will have annual sales of \$150 million within 2 years from its canine cancer test.

Even if the cancer test never wins FDA approval for human usage, introduction of the P65 canine cancer test – which requires no further clinical trials or approvals of any kind – could drive the stock as high as \$10, giving you a 900% return on our investment.

(continues...)

Company Xpention
Stock symbol XPNG
Current share price . . . \$1.09
For a FREE Investor's Kit call:
1-888-XXX-XXX

Turn \$1,000 into \$100,000 in today's new biotech mini-boom

In 2004, the Amex Biotechnology Index gained more than 11% for the year, more than doubling the 5.3% posted by the Dow.

And more than 30 biotech firms entered the U.S. market through their IPO, raising nearly \$1.8 billion.

Among the year's biotech winners:

- **A 113% profit on Eyetech Pharmaceuticals.**
- **Genitope – 89% profit.**
- **Pharmion more than tripled shareholders' money, producing a 202% profit.**
- **Biogen Idec shares gained almost 84%.**
- **142% gain on NitroMed.**
- **CoTherix also doubled, returning 99%.**

When Xpention commercializes P65 technology for the veterinary market as a test for early detection of canine and feline cancer, the stock could easily go from \$1 to \$10 a share – a gain of 900%. Product launch is



anticipated for 2007.

The FDA could approve Xpention's P65 technology, which has an accuracy rate of better than 90%, for human cancer testing as early as 2009 . . . with a cancer vaccine to follow on its heels.

When these approvals are announced, we believe Xpention could go as high as \$100 a share – giving early investors a staggering 9,900% gain.

That means an initial investment of only \$1,000 in Xpention today could grow to a whopping \$100,000 in as little as 4 years!

For a FREE Investor's Kit on Xpention (XPNG), call toll-free today 1-888-XXX-XXX.

ADVERTISEMENT

II

ALL CONTENT AND STATEMENTS CONTAINED HEREIN REGARDING XPENTION GENETICS INC. HAVE BEEN APPROVED BY MANAGEMENT OF XPENTION GENETICS INC. , AND ARE APPROVED FOR PUBLIC DISSEMINATION. THIS APPROVAL IS SUBJECT TO THE 1933 FOWARD LOOKING STATEMENT ACT AND THE DISCLAIMER ATTACHED BY:

NAME

TITLE

DATE

So in the unlikely event that Xpention *loses* the race to develop a human cancer vaccine....

You still make 10 times your money from the veterinary market for P65 technology alone – and a \$10,000 stake in Xpention could become a \$100,000 windfall.

But if I am right ... and Xpention's P65 technology is approved for human cancer testing and cancer vaccines

Then your one dollar shares of Xpention today could go as high as \$100 a share by 2009.

That means an initial investment of \$10,000 in Xpention could be worth as much as \$1 million within 4 years – as incredible as it sounds.

The bottom line: a biotech investment that gives you the astronomical upside potential of a genuine medical breakthrough ... while limiting your downside risk with profits from a secondary application of the same technology.

**Recommendation:
Buy Xpention
at the market price.**

Since this is a speculative trade, limit your position in Xpention to a small percentage of your portfolio.

For a FREE, no-obligation Investor's Kit on **Xpention (symbol: XPNG)**, or call **1-888-XXX-XXX** or visit www.xpention.com

How to buy Xpention

1. For more information on the stock, call the Xpention Investor Relations Department toll-free at **1-888-XXX-XXX** today.
2. Call your broker – or log onto your online brokerage account now.
3. Place an order for shares of Xpention – stock symbol XPNG – today, before new announcements send the stock price higher.
4. You can track the stock in your monthly issues of *Superstock Investor*.
5. Visit Xpention's Web site at www.xpention.com for the latest investor news and updates.

IMPORTANT NOTICE AND DISCLAIMER: This featured company sponsored advertising issue of Superstock Investor does not purport to provide an analysis of any company's financial position operations or prospects and this is not to be construed as a recommendation by Superstock Investor or an offer or solicitation to buy or sell any security. Xpention Genetics, Inc., (hereafter referred to as Xpention), the company featured in this issue, appears as paid advertising, subsidized by Knights Bridge Holdings, Ltd. by their description, a non-controlling shareholder, to provide public awareness for Xpention. Xpention's management has approved and signed off as "approved for public dissemination" all statements made herein regarding Xpention history, assets, technologies, current as well as prospective business operations and industry information. Although the information contained in this advertisement is believed to be reliable, Superstock Investor makes no warranties as to the accuracy of any of the content herein and accepts no liability for how readers may choose to utilize the content. Superstock Investor is not offering securities for sale. An offer to buy or sell can be made only with accompanying disclosure documents and only in the states and provinces for which they are approved. Investing in low cap penny stocks is extremely risky. You can lose all or part of your investment.

Many states have established rules requiring the approval of a security by a state security administrator. Check with <http://www.nasaa.org> or call your state security administrator to determine whether a particular security is licensed for sale in your state. Many companies have information filed with state securities regulators and many will supply investors with additional information on request. Readers should perform their own due-diligence, including consulting with a licensed, qualified investment professional or analyst. Further, readers are strongly urged to independently verify all statements made in this advertisement and perform extensive due diligence on this or any other advertised company. Capital Financial Media ("CFM") has received and managed a total production budget of \$600,000 for this print advertising effort and will retain any amounts over and above the cost of production, copywriting services, mailing and other distribution expenses, as a fee for its services. Superstock Investor also expects to receive new subscriber revenue as a result of this advertising effort.

Readers should understand that thinly traded microcap companies like Xpention, can have their share prices adversely affected by the sale of these shares.*More information can be received from Xpention's investor relations firm, or at Xpention's website at www.Xpention.com. Further, specific financial information, filings and disclosures as well as general investor information about publicly traded companies like Xpention, advice to investors and other investor resources are available at the Securities and Exchange Commission website www.sec.gov and www.nasdaq.com. Any investment should be made only after consulting with a qualified investment advisor and after reviewing the publicly available financial statements of and other information about the company and verifying that the investment is appropriate and suitable. Investing in securities is highly speculative and carries a great deal of risk especially as to new companies with limited operations and no history of earnings.

The information contained herein contains forward-looking information within the meaning of section 27a of the Securities Act of 1933, as amended, and section 21e of the Securities Exchange Act of 1934, as amended, including statements regarding expected growth of the featured company. In accordance with the safe harbor provisions of the Private Securities Litigation Reform Act, Xpention notes that statements contained herein that look forward in time, which include everything other than historical information, involve risks and uncertainties that may affect the Company's actual results of operations. Factors that could cause actual results to differ include the size and growth of the market for gold and copper, the Company's ability to fund its capital requirements in the near term and in the long term; pricing pressures, technology issues etc.

I2 ADVERTISEMENT – Please see important disclosure on page I2. Always perform your own due diligence.

ALL CONTENT AND STATEMENTS CONTAINED HEREIN REGARDING XPENTION GENETICS INC. HAVE BEEN APPROVED BY MANAGEMENT OF XPENTION GENETICS INC. , AND ARE APPROVED FOR PUBLIC DISSEMINATION. THIS APPROVAL IS SUBJECT TO THE 1933 FOWARD LOOKING STATEMENT ACT AND THE DISCLAIMER ATTACHED BY:

NAME

TITLE

DATE

(continued from page 2...)

million, the stock jumped to over \$10 a share – a gain of 60%.

- When it was reported in November of 2002 that Del Monte Foods was a take-over target, the stock price jumped 14% in just one day.
- People forget this, but in 1997, Carlos Slim, the richest man in Central America – sometimes called the Warren Buffett of Mexico – bought Apple Computer at \$17 a share. Within a year, he sold it for \$100 a share – a gain of 488.23%.
- In late 2002, Inktomi shares were languishing at 55 cents. Then Yahoo acquired the company in March 2003 for \$1.65 a share, and shareholders profited from a 206% gain.

Now, I have to warn you: our spectacular takeover profits haven't exactly escaped notice.

Over the years our editors have appeared on *Wall Street Week*, *The Nightly Business Report* and *CNBC*.

In fact, our stock picks have been reported in virtually every major financial publication in the world, including *The Wall Street Journal*, *Business Week*, *Fortune*, *Kiplinger's Personal Finance*, *Money Magazine* and others.

50% ... 119% ... 156% ... and 163% gains

In recent years, *Superstock Investor* has handed subscribers a slew of profitable takeover candidate picks, many of which were subsequently bought out at big premiums - and big profits to subscribers:

Takeover	Subscriber Profits*	Takeover	Subscriber Profits*
Paine Webber	+119% in 21 months	AXA Financial	+70% in 12 months
Donaldson Lufkin	+85% in 8 months	Pittway	+41% in 3 months
Dexter Corp.	+36% in 5 months	Brylane	+52% in 2 months
Frontier Corp.	+156% in 28 months	SJW Corp.	+100% in 10 months
Aquarion	+50% in 7 months	Arbor Drugs	+163% in 17 months

Additional companies I uncovered and recommended (in a separate service) before they were bought out, with subscriber profits:

InVision Tech.	+127% in 11 months
Burr Brown	+ 64.1% in just 1 month!
Summit Tech.	+30.6% in 9 months
Rexall Sundown.	+90.95% in 11 months
MiniMed	+35.7% in 5 months
TRW	+62.6% in 16 months

Many of these takeovers may have come as a big surprise to Wall Street, but most of them had flashed one or more of the “telltale signs” we’ve identified as often foretelling a takeover.

Other companies sported such appealing fundamentals that we wanted *Superstock Investor* subscribers to own them, whether they attracted a buyer or not!

A key benefit of our approach is that our picks span all the sectors and industries from high-flying tech stocks to conservative water utilities, to everything in between.

That means there’s built-in diversification in the *Superstock Investor* portfolio — a surefire way to lower
(continues next page...)

ADVERTISEMENT 13

the risk profile and increase the safety of any portfolio.

Also, keep in mind we'll rarely take big risks or go out on a limb to place a bet on potential takeover targets.

Again, many of our picks would be fine additions to your portfolio, with the real potential for share price appreciation, even if they never receive their first takeover offer.

Plus, we carefully structure each position to limit your risk with intelligent stops or other risk-mediating strategies.


Bottom line: We've distilled this down to a science. We conduct continuing, exhaustive research.

We've been using our proprietary signals to successfully uncover a steady flow of high-probability, low-risk takeover targets for the past 27 years — usually before Wall Street figures it out. Simply put: It works!

Try my risk-free offer!

Superstock Investor is a monthly publication that searches for the unusual and overlooked – and a risk-free subscription could be the best investment you'll make in '05 (better than XPNG?).

But to tempt you further, I'd like to offer you three free bonuses.



- **The China Bonanza: Where to Find Investment Profits of 300% to 1000%.** In many ways China's investment potential mirrors the opportunities found in the U.S. back in the late 1800s...Fascinating!
- **The Next Wave of Telecom Mergers.** The big deals have already been announced – Nextel, Cingular, etc. But the NEXT wave will sweep up the handful of smaller players, and these will offer quick profits of 50% – 100%.
- **How to Mine LEGAL Insider Information.** Detect insider buying before it's widely known. This could easily provide you with low-risk \$100,000-a-year income.

A one-year subscription costs only \$69 — a terrific bargain as it normally costs \$395 — and it includes these three special special reports. Just fill in the order page and either fax, call, or mail it back today.


Finally, I want to add that nothing should take the place of doing your own due diligence; and everything you read here and in *Superstock Investor* should be further investigated to your full satisfaction.

Remember, too, you must be delighted with *Superstock Investor* and the special reports, or notify me within 60 days and you'll receive a full refund. You've got nothing to lose...everything to gain.

Act now!

Sincerely,

Jay London
Jay London, *Superstock Investor*



P.S. TWO EXTRA BONUSES FOR TWO-YEAR SUBSCRIBERS!

- (1) Retiring Rich, by Dr. Michael Alexander. This book shows you how to adjust your asset strategy to fit any economic cycle...valued at \$79...yours FREE!
- (2) ELECTRONIC DATABANK mini-computer. Many features...regular value \$150...yours FREE with a two-year subscription. That's a total value of \$526 in free gifts!

14 ADVERTISEMENT – Please see important disclosure on page 12. Always perform your own due diligence.

ALL CONTENT AND STATEMENTS CONTAINED HEREIN REGARDING XPENTION GENETICS INC. HAVE BEEN APPROVED BY MANAGEMENT OF XPENTION GENETICS INC. , AND ARE APPROVED FOR PUBLIC DISSEMINATION. THIS APPROVAL IS SUBJECT TO THE 1933 FOWARD LOOKING STATEMENT ACT AND THE DISCLAIMER ATTACHED BY:

NAME _____ TITLE _____ DATE _____

SUPERSTOCK Investor Risk-Free Request Form

YES, send me *Superstock Investor* – the monthly publication that’s been helping investors find double – and triple-digit gains for the past quarter-century. Please send me the free bonuses. I must be delighted or you will refund all my money if notified within 60 days. The special reports are mine to keep regardless, but the book and databank must be returned.

- BEST OFFER:** Two-year subscription with 5 FREE gifts, just \$119. (Regular rate \$695)
- GOOD OFFER:** One-year subscription with 3 FREE gifts, just \$69. (Regular rate \$395)
- Early Bird Bonus:** Subscribe within seven days and you’ll receive 24-hour access to the *Superstock Investor* website and confidential email updates. Act quickly on recommended trades for rich potential profits!

Your Guarantee

You must be delighted with *Superstock Investor*. If not, contact us to cancel your subscription within 60 days and receive a complete refund — no questions asked!

Name

E-mail Address (required)

Address

City/State/Zip Code

Payment Options

- My check/money order made payable to *SuperStock Investor* is enclosed.
- Charge my credit card: VISA Mastercard American Express

Credit Card Number

Exp. Date

Signature

Phone number (in case we have questions about your order)

4 Easy Ways to Subscribe

For fastest service call toll-free **1-800-894-3424** or **1-561-395-9495**

Or fax your order to **1-612-395-5250**

Or order immediately online at www.superstockinvestor.com/order2/ss0305

Please mail your complete subscription application in the enclosed envelope.

If the envelope is missing, mail to:

SuperStock Investor, 925 S. Federal Hwy, Suite #500, Boca Raton, FL 33432

ADVERTISEMENT

ALL CONTENT AND STATEMENTS CONTAINED HEREIN REGARDING XPENTION GENETICS INC. HAVE BEEN APPROVED BY MANAGEMENT OF XPENTION GENETICS INC. , AND ARE APPROVED FOR PUBLIC DISSEMINATION. THIS APPROVAL IS SUBJECT TO THE 1933 FOWARD LOOKING STATEMENT ACT AND THE DISCLAIMER ATTACHED BY:

NAME

TITLE

DATE

Earn a staggering 9,900% profit from the first cancer vaccine that *actually works*...as incredible as that sounds!



The \$1 cancer stock that **could go to \$100 a share within 3 years – and why you can't lose!** Page 10

How to **gain a quick 900% profit** from "P65" Biotechnology..... Page 11

Cancer breakthrough: new treatments from the world's most respected University cancer center..... Page 7

Test 60 million dogs annually at \$25 each. You do the math and **calculate the profits.** . Page 6

The amazing biotech company that can **make you healthy and make you rich!** Page 4

SUPERSTOCK Investor

925 S. Federal Hwy., Suite #500
Boca Raton, FL 33432




ALL CONTENT AND STATEMENTS CONTAINED HEREIN REGARDING XPENTION GENETICS INC. HAVE BEEN APPROVED BY MANAGEMENT OF XPENTION GENETICS INC. , AND ARE APPROVED FOR PUBLIC DISSEMINATION. THIS APPROVAL IS SUBJECT TO THE 1933 FOWARD LOOKING STATEMENT ACT AND THE DISCLAIMER ATTACHED BY:

NAME

TITLE

DATE

SUPERSTOCK Investor



EUREKA!!

Discovered: The Most Important Medical Breakthrough of The 21st Century!

I'm *beside* myself...

A group of brilliant doctors has just made a startling discovery: Almost ALL cancer patients, regardless of what form of cancer, experience elevated levels of a substance in the body known as "P65."

...Your body only makes P65 in significant quantities when cancer is present... BUT this tiny R&D company has discovered a chemical agent that effectively blocks the production of P65 — HALTING further growth of cancer cells!

In a well-equipped laboratory at a major university, a small group of scientists recently made an amazing discovery.

They found that, almost universally, all cancer patients have an elevated level of a substance in the body known as "P65."

P65 is a special type of protein molecule, made in the body in significant quantities only when cancer is present.

Its production is controlled by a specific gene, which the research team has identified; let's call it the

(continues on page 3...)

Could This Be the World's First Cancer Vaccine??

ALL CONTENT AND STATEMENTS CONTAINED HEREIN REGARDING XPENTION GENETICS INC. HAVE BEEN APPROVED BY MANAGEMENT OF XPENTION GENETICS INC. , AND ARE APPROVED FOR PUBLIC DISSEMINATION. THIS APPROVAL IS SUBJECT TO THE 1933 FOWARD LOOKING STATEMENT ACT AND THE DISCLAIMER ATTACHED BY:

NAME

TITLE

DATE